secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059668
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta Therapeutics appoints Michael Faerm as CFO, base salary $480K with stock options
--------------------------------------------------------------------------------

- Michael Faerm appointed CFO effective May 13, 2024; previously interim CFO at Harpoon Therapeutics.
- Annual base salary $480,000, target bonus up to 40% of base salary.
- Initial option to purchase 500,000 shares of common stock, vesting over 4 years.
- Additional option for 340,000 shares if financing extends runway through FY2025 by Dec 31, 2024.
- Board increased shares reserved under Inducement Plan by 1,200,000, total 3,575,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/virx-20240511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer